Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vemurafenib - Roche

Drug Profile

Vemurafenib - Roche

Alternative Names: PLX-4032; R-7204; RG-7204; RO-5185426; Zelboraf

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Chugai Pharmaceutical; Genentech; Georgetown University; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Melanoma Research Alliance; Memorial Sloan-Kettering Cancer Center; Plexxikon; Roche; University College London; University Hospital Tubingen
  • Class 2 ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Registered Immunological disorders
  • Phase II Brain metastases; Colorectal cancer; Haematological malignancies; Multiple myeloma; Non-small cell lung cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (PO)
  • 13 Dec 2018 Phase-II clinical trials in Brain metastases (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in Italy, France, Latvia, Hungary, Spain (PO)(NCT03625141)(EudraCT2018-000759-41)
  • 10 Sep 2018 Genentech completes a phase I trial in Malignant melanoma (Late-stage disease, First-line therapy, Combination therapy) in USA, Israel, South Korea and Russia (PO) (NCT02608034)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top